ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)

Eli Lilly's obesity drugs drove massive revenue growth for the company. The pharmaceutical giant reported significant financial gains driven by its weight-loss treatments. The drugs' strong market performance boosted overall earnings substantially.
Tap to vote and see what everyone thinks.
Summary by ByteBrief